NCT00003292

S9624 Ifosfamide in Treating Patients With Meningeal Tumors

S9624: Phase II Study of Ifosfamide in Patients With Aggressive Meningeal Tumors

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: SWOG Cancer Research Network · Network
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ifosfamide in treating patients with meningeal tumors that have recurred or that cannot be removed surgically.

Detailed description

OBJECTIVES: * Estimate failure free survival, overall survival, and response in patients with residual or recurrent/progressive aggressive meningeal tumors (malignant meningioma, hemangiopericytoma, and primary nervous system sarcoma) treated with ifosfamide. * Evaluate toxicities of ifosfamide in this patient population. OUTLINE: All patients receive ifosfamide IV continuously over 72 hours on days 1-3 of each 21 day treatment course. Patients are evaluated for response/progression after every 2 courses. Patients with stable disease receive up to 8 courses of therapy. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year, then every 6 months thereafter. PROJECTED ACCRUAL: Approximately 35 patients will be accrued for this study.

Conditions

• Chondrosarcoma
• Adult Fibrosarcoma
• Adult Leiomyosarcoma
• Adult Rhabdomyosarcoma
• Adult Malignant Meningioma
• Adult Brain Malignant Hemangiopericytoma

Interventions

Type	Name	Description
DRUG	ifosfamide

Timeline

• Start date: 1998-07-01
• Primary completion: 2004-01-01
• Completion: 2004-01-01
• First posted: 2003-01-27
• Last updated: 2013-11-08

Locations

70 sites across 4 countries: United States, Australia, Peru, Puerto Rico